Abrinica, Clyde .

HRN: 27-22-75  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/12/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
06/12/2025
06/15/2025
IV
350mg
Q6h
PCAP
Pending Pharmacy Acceptance 

 Indication:  Empirical Escalation    Type of Infection:  Pneumonia    Compliance to guidelines: